ProofPilot’s acquisition of Lokavant will have a strong, direct impact on clinical trial performance and outcomes.
On the heels of the acquisition announcement, Chris Venezia, ProofPilot CEO, and Joseph Kim, Chief Strategy Officer, spoke with Clinical Trial Vanguard about the problems the combined platforms will solve. They also explained how it can create real value for sponsors.
From reliable, real-time decision-making to proactive interventions, here is what the two tools can do when they work together.
ProofPilot's acquisition of Lokavant brings day-to-day trial work and advanced analytics into one end-to-end dashboard. The merged platform works like an action map, linking leading and lagging signals so teams can turn forecasts into focused training or process changes. It also supports clinical trial optimization across studies.
With live tracking that links site behavior to outcomes, sponsors can act early. They can cut deviations, speed up improvement, and lift study quality. The interview with Clinical Trial Vanguard highlights how this approach can support faster decisions and clear value in current and future trials.
ProofPilot’s bread and butter is enabling flawless day-to-day trial execution. Lokavant is strong in reporting, analytics, and forecasting. This means the merge is not about overlap, but it is about fit.
The combining of the two platforms aims to give teams one simple dashboard that links operational actions to predictive insights, with outcomes based in clinical data. The result is a practical framework for higher quality trials, faster decisions, and measurable outcomes.
What we're creating is not just another dashboard. The product is a reliable action framework that joins leading signals with lagging results so teams can turn forecasts into real steps that drive better outcomes.
Here’s how it works:
This helps teams test new steps, watch the result, and adjust in real time.
“Imagine a site deviation where the platform can trace it back to a clear cause,” Chris said. “Certain content that was not accessed, what guidance was consulted, and how interpretations may have diverged.”
In simple terms, the goal is to make cause and effect easy to see. For fixes to work again and again, sponsors need a way to link day-to-day use and behavior with outcomes.
With full end-to-end visibility, sponsors can better see what actions lead to what impact.
“Real-time traceability means you don’t wait for an audit to know what happened,” Joe said in the interview.
Teams can make clear gains in study conduct when behavior signals trigger prompt intervention before it’s too late. This leads to fewer repeat mistakes and faster improvement.
Think proactive prevention rather than reactive fixes—and not only for the current study, but future studies as well.
Read Chris and Joe’s full interview with Clinical Trial Vanguard for a deeper exploration of the strategy behind the acquisition.
Check out our Enrollment Forecaster for a deeper dive into the capabilities born out of the acquisition.
For extra credit, book a call with us to discuss how our end-to-end platform can transform your study conduct.
What is the main value of ProofPilot's acquisition of Lokavant?
It joins ProofPilot's day-to-day trial work with Lokavant's advanced analytics and forecasting in one end-to-end dashboard. This action map links leading signals with lagging results so teams can turn forecasts into focused training or process changes and see clear gains across studies.
How is the ProofPilot and Lokavant integration different from just another dashboard?
Instead of only showing data, the platform puts it to work. By joining forecast insight with real-time action, it closes the loop between signal and result. Teams can make specific changes, track impact, and keep improving study conduct with clear cause and effect.
What real value can sponsors expect now and in future trials?
Faster choices, fewer deviations, early action, and clearer links between site behavior and outcomes. The gains seen in current studies can carry into future trials, which supports smarter prevention and better execution. For more detail, read the Clinical Trial Vanguard interview or book a call to explore the end-to-end platform.